Introduction
============

Device-based hypertension treatment is a complementary and possibly alternative approach to conventional lifestyle changes combined with antihypertensive medications to achieve and maintain optimal blood pressure (BP) control. A series of clinical trials assessing novel technologies are currently ongoing for device-based hypertension treatment, including endovascular catheter-based renal denervation (RDN), baroreceptor activation therapy, endovascular baroreflex amplification, and cardiac pacemaker-mediated hypertension treatment.

Only a few years ago, RDN was written off as ineffective after results of the sham-controlled SYMPLICITY HTN-3 trial[@ehaa121-B1] failed to confirm early trials' reports of significant BP reductions in patients resistant to guideline-based combination drug therapy. However, the trial's design and execution has been questioned by many. Later-on, following recommendations provided by European and US expert groups,[@ehaa121-B2] defining optimal trial design and methodology and the population of patients to be included, three carefully designed, randomized sham-controlled RDN trials (SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, and RADIANCE-HTN SOLO)[@ehaa121-B5] reported consistent, plausible, and clinically meaningful ambulatory and office BP reductions in the short- (2 to 3 months) and mid-term (6 months) with radiofrequency (RF)- or highly focused ultrasound (US)-based RDN while reporting no serious adverse events. These exploratory phase II studies included selected patients with uncontrolled hypertension who were both on and off medications to demonstrate both biological proof of principle (off medications) but also context in routine clinical practice (on medications). With rigorous trial oversight and methods, these studies provided consistent and robust proof for BP lowering efficacy of RDN.

Against this background, the 3rd European Clinical Consensus Conference for device-based therapies for hypertension was held in July 2019 in Mainz, Germany. The aims were to identify key issues and provide consensus recommendations for the design and conduct of new, clinically more relevant, pragmatic trials to move forward with the investigation of device-based hypertension therapies, and to establish what evidence is needed for potential clinical adoption of these technologies (*Figure [1](#ehaa121-F1){ref-type="fig"}*). Considerations on how to interact with regulatory and reimbursement authorities were also discussed. The current document summarizes the discussion and consensus views. It focuses on research and development issues and is not a guide to clinical practice ([*Take home figure*](#ehaa121-F4){ref-type="fig"}).

![Explanatory vs. pragmatic trial on the example of RDN. Adapted from Thorpe *et al*.[@ehaa121-B9]](ehaa121f1){#ehaa121-F1}

![Summary of research and development challenges in device-based hypertension treatment.](ehaa121f4){#ehaa121-F4}

Current and emerging treatments for renal denervation
-----------------------------------------------------

Multipolar RF- and US-based RDN were shown to be safe and effective in randomized, controlled trials with the use of second-generation devices (*Table [1](#ehaa121-T1){ref-type="table"}*).[@ehaa121-B5] The choice of these newer technologies and ablation techniques has the potential to provide more consistent and effective renal nerve ablation than the first-generation of catheters. The failure of efficacy with RDN in the SYMPLICITY HTN-3 trial was extensively discussed by experts in the field and was attributed to various possible factors, including patient selection, changes in medication prescription and adherence, insufficient and varying operator experience, and suboptimal procedural performance with the first-generation monopolar Symplicity flex catheter.[@ehaa121-B4] Using a modified multielectrode RF-RDN catheter, SPYRAL HTN-OFF MED[@ehaa121-B5] and SPYRAL HTN-ON MED[@ehaa121-B8] included blood and urine sampling to ensure adherence with 'on drug' or 'off drug' designs. SPYRAL HTN-OFF MED (*n* = 80) was a randomized, sham-controlled feasibility trial with a 3- to 4-week drug washout period and a 3-month follow-up period in the absence of antihypertensive medications. SPYRAL HTN ON-MED (*n* = 80) was a randomized, sham-controlled feasibility study with a 6-month follow-up period in which patients were treated with one to three commonly prescribed antihypertensive drugs. A pivotal trial with the multielectrode Spyral RF-catheter in the off medications indication is ongoing (NCT02439749), in addition to a large, randomized trial in the on medications setting. RADIANCE-HTN SOLO[@ehaa121-B6] was a powered, sham-controlled trial with a US-based RDN device which randomized 146 patients with combined systolic and diastolic hypertension after a 4-week washout period and who remained off antihypertensive medication during the first 2-month follow-up. The study met its primary efficacy and safety endpoints at 2 months. At 6-month, results confirmed the maintenance and the durability of BP lowering efficacy with US-based RDN. Fewer protocol-defined antihypertensive medications were administered from to 2 to 6 months in the RDN than in the sham group, and after accounting for these medication differences, RDN had greater ambulatory BP lowering efficacy than the sham procedure.[@ehaa121-B10] Three other adequately powered trials with US-RDN are ongoing, including the RADIANCE TRIO (NCT02649426) trial in patients with resistant hypertension despite receiving three antihypertensive medications in a single combination,[@ehaa121-B11] the REQUIRE trial evaluates patients with resistant hypertension on standard of care medication in Japan and Korea (NCT02918305), and the pivotal RADIANCE II trial in patients with uncontrolled hypertension while on one or two medications (NCT03614260). These two methods of renal artery ablation were compared in patients with resistant hypertension in the open label randomized RADIOSOUND trial.[@ehaa121-B12] This trial showed that US-based RDN of the main renal arteries had (i) a similar BP lowering efficacy as RF-based RDN of the main renal artery plus its branches as well as accessory renal arteries and (ii) a greater BP lowering efficacy than RF-based RDN of the main renal arteries only.

###### 

Blood pressure reductions with RDN in recently completed sham-controlled trials

                                         SPYRAL HTN-OFF MED   SPYRAL HTN ON-MED   RADIANCE-HTN SOLO                          REDUCE HTN: REINFORCE
  -------------------------------------- -------------------- ------------------- ------------------------------------------ ----------------------------------------------
  Follow-up data published               3 months             6 months            6 months                                   6 months
  Sham-control                           Yes                  Yes                 Yes                                        Yes
  Adherence measurements                 Yes                  Yes                 No                                         No
  Feasibility/powered                    Feasibility          Feasibility         Powered, primary endpoint (2 months) met   Powered, primary endpoint (2 months) not met
  Patients randomized                    80                   80                  146                                        51
  Difference in BP RDN vs. sham (mmHg)                                                                                       
   24-h SBP                              −5.0                 −7.0                −4.1                                       −7.2
   *P*-value                             0.041                0.006               0.006                                      0.083
   24-hr DBP                             −4.4                 −4.3                −1.8                                       −3.6
   *P*-value                             0.002                0.017               0.07                                       0.172
   Daytime SBP                           −5.4                 −6.1                −6.3                                       −9.7
   *P*-value                             0.057                0.018               \<0.001                                    0.021
   Daytime DBP                           −3.9                 −4.1                −2.6                                       
   *P*-value                             0.039                0.03                0.01                                       
   Office SBP                            −7.7                 −6.6                −6.5                                       −11.4
   *P*-value                             0.016                0.025               0.007                                      0.006
   Office DBP                            −4.9                 −4.2                −4.1                                       −5.4
   *P*-value                             0.008                0.02                0.005                                      0.037

Despite demonstrated efficacy of both approaches, there was large between-patient variation of responses to RDN even in these optimally designed trials. This might be due still to the variable degree of renal nerve ablation achieved with these technologies in the absence of a peri-procedural marker of success or due to a lesser contribution of sympathetic renal nerve activity to the underlying pathophysiology of hypertension in individual patients.[@ehaa121-B13]

Further information about the efficacy of RDN came from the REDUCE HTN:REINFORCE trial with the balloon-based bipolar RF-based Vessix system (NCT02392351). Recruitment to this study with 'off drug' design was stopped for futility of achieving a significant difference between the RDN- and the sham-group at the predefined 8-week primary endpoint. At 6 and 12 months, however, a significant difference in office BP reduction in favour of RDN was reported.[@ehaa121-B14] A number of ablative and non-ablative technologies are in development and may complement today's devices in the future (*Table [2](#ehaa121-T2){ref-type="table"}*).

###### 

Available and developmental device-based hypertension technologies

  Technology                                     Demonstrated efficacy and safety
  ---------------------------------------------- ----------------------------------------------------------------------------------------
  Radiofrequency RDN                             Yes
  Ultrasound RDN                                 Yes
  Alcohol-mediated RDN                           Under investigation
  Arteriovenous anastomosis (ROX Coupler)        Withdrawn because of high rates of venous stenosis and volume overload (heart failure)
  Baroreceptor reflex stimulation (CVRx)         Under investigation
  Baroreceptor reflex amplification (MobiusHD)   Under investigation
  Pace-maker-mediated hypertension treatment     Under investigation

Endovascular catheter-based alcohol-mediated RDN is currently under investigation in patients with and without concomitant antihypertensive medication (TARGET BP-OFF, NCT03503773, TARGET BP I, NCT02910414). The results from the open-label, feasibility study in 45 patients with uncontrolled hypertension on multiple antihypertensive medication indicate significant reductions in office and ambulatory BP 6 months following bilateral injection of 0.6 mL alcohol in the perivascular space.[@ehaa121-B15]

In comparison to RDN, alternative methods of device-based therapies for treatment of hypertension are presently being studied. Asymmetric ventricular pacing using a dedicated dual-chamber pacemaker aims to reduce BP through varying atrioventricular coupling intervals. The effect can be modulated by modifiable pacing parameters. The open-label, single-arm Moderato study showed promising positive results.[@ehaa121-B16] In an uncontrolled, proof-of-concept study, endovascular baroreceptor amplification with the Mobius HD device (Vascular Dynamics, Mountain View, CA, USA) implanted in patients with resistant hypertension taking at least three antihypertensive agents showed a significant reduction in BP at 6 months.[@ehaa121-B17] A randomized, sham-controlled study in patients with resistant hypertension in currently ongoing (NCT03179800).

For several of these technologies, the lack of a control group in the initial trials places them at a similar promising stage as RF-based RDN in the early 2010s and with the same need for additional rigorous confirmatory trials. Finally, not only efficacy but above all safety needs to be demonstrated when these devices are used especially in patients with the milder forms of hypertension who are at lower risk for cardiovascular (CV), cerebrovascular, and renal events in the short- and mid-term.[@ehaa121-B18] Even a very small risk of adverse events (e.g. \>1/1000 patients) would be unacceptable for patients with mild hypertension. For example, with the ROX coupler, which adds a low-resistance, high-compliance venous segment to the central arterial tree to exploit the natural mechanical effects, significant BP lowering efficacy was shown at 6 months and sustained at 12 months.[@ehaa121-B19]^,^[@ehaa121-B20] However, up to 30% of patients developed venous stenosis at the insertion site and a heart failure (HF) signal was observed during long-term follow-up in the active group vs. control patients, which led to termination of the pivotal ROX HTN 2 trial and an uncertain future for this approach.

Both the 2017 North-American and the 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) Guidelines[@ehaa121-B21] for the management of arterial hypertension state that the use of device-based therapies is not recommended for the routine treatment of hypertension outside of clinical studies as the evidence available at the time of writing of the guidelines was considered not informative enough but called for further sham-controlled trials of device-based therapies.

Who should be investigated in device-based hypertension trials?
---------------------------------------------------------------

The primary guiding rule when selecting the appropriate patient population for each specific device/technology is that the procedural risk must not exceed the underlying risk of the untreated condition for each individual patient. This is particularly relevant since a class effect likely does not exist with device therapies for hypertension, and each much be considered on their individual risks. As priority candidates for further clinical trials, this group considered targeting high-risk hypertensive patients with coronary artery disease (CAD), chronic kidney disease (CKD), diabetes, and other comorbidities, followed by studies in patients with masked hypertension or white-coat hypertension. For everyday clinical care, patients with difficult-to-control hypertension remain at the greatest need for device-based hypertension therapies, particularly in the setting of widespread non-adherence with drug therapy; whereas a second priority in daily care may be to provide access for high-risk patients, as well as those with mild-to-moderate hypertension in presence of hypertension-mediated organ damage (HMOD) or severe comorbidities.

Given the mid-term safety and efficacy of RDN in patients with mild--moderate-risk documented recently,[@ehaa121-B5] it may be reasonable to start investigating device-based therapies in other populations. A non-exhaustive list of potential candidates for future research activities is shown in *Table [3](#ehaa121-T3){ref-type="table"}*.

###### 

Current and potential candidate hypertensive populations for RDN therapy

+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| Patient group                                                                                                        | Pro                                                                                                | Con                                                                                                                                          |
+:=====================================================================================================================+:===================================================================================================+:=============================================================================================================================================+
| ***Current candidates***                                                                                             |                                                                                                    |                                                                                                                                              |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| Difficult-to-control hypertensive patients (with office SBP between 140 and 170 mmHg or DBP between 90 and 109 mmHg) | Current target populationSolid evidence base                                                       | Narrow group                                                                                                                                 |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| ***Potential candidates***                                                                                           |                                                                                                    |                                                                                                                                              |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| CAD patients                                                                                                         | Very high-risk patientsLow rates of BP control in daily care                                       | Prolonged procedure (PCI + RDN)                                                                                                              |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| Cancer survivors                                                                                                     | Many cancer treatments can induce hypertensionHTN is a risk factor for the toxicity of other agent | Need for RDN not proven                                                                                                                      |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| HIV patients                                                                                                         | Already under major pill burdenDrug--drug interactionPreviously neglected group                    | Recruitment challengesNeed for RDN not proven                                                                                                |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| White-coat hypertension on medications                                                                               | High-risk groupsLarge population                                                                   | Untested therapy in this populationUncertain reproducibility of current data on riskNot well-recognized as candidatesNeed for RDN not proven |
|                                                                                                                      |                                                                                                    |                                                                                                                                              |
| Masked hypertension off and on medications                                                                           |                                                                                                    |                                                                                                                                              |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+
| White-coat hypertension off medications                                                                              | Many will develop chronic hypertensionLarge population                                             | Untested therapy in this populationUncertain reproducibility of current data on riskNot well-recognized as candidatesUnmet need not proven   |
+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------+

CAD, coronary artery disease; HIV, human immunodeficiency virus; HTN, hypertension; PCI, percutaneous coronary intervention.

In addition, a number of other potential candidates have been discussed:

1.  Patients with CAD undergoing percutaneous coronary revascularization represent a high-risk group with an unmet need for efficient therapies to achieve recommended rates of BP control.[@ehaa121-B21]^,^[@ehaa121-B22] Coronary artery disease patients have increased CV risk, which makes this a particularly interesting population for future studies, also to investigate the impact of device-based hypertension therapy on the residual CV risk and CV events within a short period of follow-up. Specifically, there is evidence of antiarrhythmic effects of RDN which would be particularly suitable in this patient population.

2.  An increasing number of patients express a strong preference to be treated with a non-pill based therapy instead of receiving pharmacotherapy. Patient preference for an alternative to pharmaceutical therapy because of drug intolerance/side effects, social, economic, or other reasons suggests these patients may be appropriate candidates for device-based hypertension treatments.

3.  Due to improved treatments, cancer survivors are more prevalent, live longer with better quality of life, however, are exposed to long-term consequences of CV toxicity including hypertension and HF as a number of targeted anticancer treatments, old as well as new, can induce hypertension.[@ehaa121-B24]

4.  With the widespread use of antiretroviral therapy and thereby improved prognosis, patients with human immunodeficiency virus (HIV) experience CV illnesses, with high rates of uncontrolled and complicated hypertension.[@ehaa121-B25]^,^[@ehaa121-B26] As HIV therapy already imposes a substantial pill burden with a risk of various drug--drug interactions, device-based therapies may be a favourable option in these individuals.

5.  Both 'white-coat' hypertension (elevated clinic and normal 24-h ambulatory BP) found in 30--40% of patients (and \>50% in the very old) and untreated masked hypertension (normal clinic and elevated 24-h ambulatory BP) found in approximately 15% of patients with a normal office BP, have been shown to be associated with elevated mortality risk,[@ehaa121-B21]^,^[@ehaa121-B23] with masked hypertension conferring even a greater risk than sustained hypertension.[@ehaa121-B27]^,^[@ehaa121-B28] It should be discussed whether intervention in white-coat hypertension might provide an early prevention strategy to avoid entering the stage of sustained or masked hypertension.

Of note, a number of additional factors need to be considered to treat these potential new populations with device-based therapies of hypertension. Many of these individuals are rarely seen by physicians specialized in hypertension treatment and the unmet need is often not felt as such; this also includes assessment of patients' own preferences. Similarly, regulatory and reimbursement authorities may have a greater understanding of the indication of device-based therapies in patients with severe, complicated or resistant forms of hypertension, and may not feel comfortable with discussing expanded indications at the present time and cost of the therapy. Targeted studies will have to be carefully designed in order to demonstrate relevant efficacy, safety and value (cost effectiveness) in populations beyond those included in the successful clinical trials to date. For example, for higher-risk individuals, the option of baroreflex amplification is being investigated while awaiting the results of the ongoing RDN trials listed above, bearing in mind that the safety profiles of these devices have not yet been fully established.

Consensus statement 1: Selection of hypertensive patients for device-based therapies
------------------------------------------------------------------------------------

-   When selecting the appropriate device-based hypertension therapy for each individual patient, the procedural risk must not exceed the risk from the underlying condition itself.

-   In everyday clinical care, patients with difficult-to-control hypertension may benefit most from device-based hypertension therapies. Patients need to be provided with balanced information concerning the variability of the BP response and the unknown BP lowering effect and safety in the long-term.

-   In the short-term perspective (2--3 years), the most appropriate population for further clinical trials in device-based hypertension treatment should be high-risk hypertensive patients with comorbidities including CAD, diabetes, and CKD.

-   A changed focus from severe and resistant hypertension towards embracing other groups with mild to moderately elevated BP should be considered in the future.

Design of clinical trials in renal denervation
----------------------------------------------

### Endpoint selection beyond blood pressure reduction

Appropriate pivotal trials to demonstrate BP lowering efficacy is a *sine qua non* requirement for any emerging treatment. To demonstrate value beyond BP reduction, trials should target the common endpoints for CV therapies, e.g. CV morbidity/mortality, improvement in HMOD, as shown for the different classes of antihypertensive medications.[@ehaa121-B29] These endpoints further need to allow for a treatment effect to be ascertained within reasonable follow-up. However, with increasing attention being paid to patients' perspectives these outcomes alone are unlikely to be sufficient in future. Indeed, endpoints which matter most to patients are not necessarily the same as those prioritized by physicians. For device-based hypertension therapies, this becomes especially important, as devices compete with non-invasive treatments which have lower acceptance threshold, particularly in lower-risk patients. Among BP-related events, patients care about stroke, dementia and cognitive deficits, myocardial infarction and HF, and end-stage renal disease which makes these core endpoints very relevant for inclusion in future trials of device-based hypertension therapies.[@ehaa121-B30] For device-based hypertension therapies to become widely acceptable to patients and clinicians, it will need to be demonstrated that the CV benefits conferred by device therapies do not come at the cost of patient-reported side effects or other adverse outcomes (including side-effects to medications), and adapting treatment to their preferences and context.[@ehaa121-B31] There is a growing realization among medical professionals that patient-reported outcomes (PROs) reflect a key dimension of overall disease burden. Patient-reported outcome measurements are increasingly included in clinical trials.[@ehaa121-B32] Patient-reported outcomes need to be handled and analysed as stringently as any other data and should be reported in accordance with the CONSORT PRO Extension.[@ehaa121-B33] They must be reported by the patient and not by the physician. The use of PRO measures is discussed further below. We are lacking validated PRO questionnaire for HTN, accounting for importance and different relevance in various cultures. Patients should be involved in the trial design and endpoint selection of studies using PRO.

Consensus statement 2: Endpoints and outcomes
---------------------------------------------

-   Evidence is needed on patient-relevant outcome benefits from BP reduction with device-based hypertension therapies. The risk profile of the study population and the relevant outcome measures of such trials need to be defined.

-   An unstudied opportunity is to survey PRO measures in hypertension. Device-based hypertension therapy needs to deliver outcomes that matter to patients. The attention to patient preferences in future clinical trial design should be encouraged.

-   Patient preference information and quality of life assessments are mandatory to further determine the potential benefits and risks for devices. In addition, there remains a need to develop measures of patient-reported health status specific to device-based therapies for hypertension.

-   Capturing PROs in clinical trials should be encouraged and measures should be reported in accordance with the CONSORT PRO Extension.[@ehaa121-B33]

### Screening for potential candidates

The main anatomical exclusion criterion for RDN is renal artery stenosis of any origin (atherosclerosis, fibromuscular dysplasia, and others). Although the prevalence of renal artery stenosis is very low in mild to moderate hypertension, in referral groups with higher uncontrolled BP despite antihypertensive treatment, the prevalence may be up to 30%.[@ehaa121-B34]^,^[@ehaa121-B35] Patients considered for RDN undergo renal artery anatomical screening to confirm anatomical eligibility criteria. Even though the screening method preferred by most physicians is duplex ultrasound (DUS), which has the advantages of lack of exposure to radiation or contrast dye, it has several limitations including operator-dependency, and often lack of visualization of the main renal artery over its entire length.[@ehaa121-B36] For clinical diagnosis and follow-up, DUS may not represent the best option, as computed tomography angiography (CTA) or magnetic resonance angiography may be needed for confirmation of anatomical eligibility as well as detection of adrenal tumour or hyperplasia, completing thus the necessary diagnostic workup for secondary hypertension especially in the context of resistant hypertension.[@ehaa121-B21] However, pulmonary computed tomography (CT) was reported to carry a non-negligible cancer risk of 1/1250 to ∼1/5000[@ehaa121-B37] which would be unacceptable for screening purposes. The newer third-generation dual-source CT systems for CV imaging purposes are associated with much lower radiation exposure and contrast injection than conventional CTA. Magnetic resonance angiography with gadolinium-based contrast agents may be an alternative to CTA but the technology is hindered by many false positives for renal artery stenosis, and exposure to the unknown long-term consequences of gadolinium accumulation in the brain.[@ehaa121-B38] For the future, fusion of post-processed images in conjunction with real-time fluoroscopy is an emerging modality which promises short procedural time, low contrast volume, and catheter manipulation. Whenever possible, core laboratories, blinded to patient's characteristics, should be used for imaging data analyses. A reasonable screening pathway with current technologies is depicted in *Figure [2](#ehaa121-F2){ref-type="fig"}*.

![Suggested algorithm for identification of RDN candidates for clinical trials. CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic resonance angiography.](ehaa121f2){#ehaa121-F2}

### Predictors of response

A difficulty is the lack of standardized definitions of response for use in patient identification and selection for device-based treatment of hypertension. Ambulatory BP and office BP are both used as primary efficacy parameters in device-based trials of hypertension. The group earlier recommended using 10 mmHg reduction in office systolic BP (SBP) or 6--7 mmHg in daytime or 24-h ambulatory SBP for the purpose of power calculations in hypertension device trials. These BP reductions are considered clinically meaningful[@ehaa121-B4] since a 10 mmHg reduction in office SBP is associated with reduced risk of major CV disease events by up to 20%, coronary heart disease by 17%, stroke by 27%, and HF by 28%.[@ehaa121-B29] The time to the response analysis may also affect how a responder is characterized and should ideally be comparable between trials. Most often the timepoint for primary endpoint evaluation spanned over from 2--3 months to 6 months. The futility analysis in REDUCE HTN: REINFORCE was performed on an 8-week endpoint, whereas a similar analysis at 6 months would have permitted the trial to continue and in all probability report a positive result.[@ehaa121-B39]^,^[@ehaa121-B40]

The variability in BP response in the clinical trials was rather large, with 20--30% of patients experiencing above-average BP reductions within 3 months after the procedure.[@ehaa121-B5]^,^[@ehaa121-B6] It has been pointed out that this holds true even in patients not treated with concomitant medication.[@ehaa121-B41] A number of possible confounders may influence the short- and long-term treatment effect, e.g. the variable contribution of the sympathetic nervous system (SNS) to BP elevation in the individual patient, genetic background, comorbidities, or accompanying treatments. Currently available study data do not provide much information to help predict response. A large number of potential predictors are available (*Table [4](#ehaa121-T4){ref-type="table"}*) but of those, the association between baseline BP and increased BP reduction has been the only consistent finding in RDN trials, which is a well-known phenomenon observed with any type of antihypertensive treatment.[@ehaa121-B42]^,^[@ehaa121-B43] It remains elusive how much of this effect can be attributed to regression to the mean.[@ehaa121-B44] In RADIANCE-HTN SOLO,[@ehaa121-B6] there was correlation between a greater number of previous antihypertensive medications before washout and greater reduction in ambulatory SBP, but the number of drugs may be a proxy for severity of BP.

###### 

Potential predictors of response to RDN therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Baseline characteristics** Systolic blood pressure AmplitudeVariabilityCombined versus isolated systolic hypertensionPulse wave velocityHeart rate Basal rateVariabilityAntihypertensive medicationPoor drug adherence despite extensive counsellingEthnicityRisk factors Obstructive sleep apnoeaChronic kidney diseaseObesity
  **Procedural variables** Number of treatment ablationsAnatomic site Distal branch vessels for RF treatmentAccessory renal arteries
  **Biomarkers** Ghrelin, MR-proadrenomedullin, Neuropeptide-Y, Brain-derived neurotrophic factor, intercellular cell adhesion molecule-1 (ICAM), vascular cell adhesion molecule-1 (VCAM)mircoRNAMuscle sympathetic nerve activity
  **Invasive**/**provocative testing**Renal resistance and wave speedDrug challenge (e.g. clonidine)Baroreceptor sensitivityBlood pressure response to orthostasisElectrical renal nerve stimulation
  **Imaging** Meta-iodobenzylguanidine scintigraphy (kidney/heart)Renal artery diameterPresence of accessory arteries
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In SPYRAL HTN-OFF MED, ambulatory heart rate (HR) above the median (\>73.5 b.p.m.) was predictive of reduction in average daytime SBP, daytime diastolic BP, and office SBP.[@ehaa121-B45] Heart rate may represent a sign of SNS activation and is predictive of incident HF in hypertensive patients.[@ehaa121-B46] HF patients with elevated HR are at increased risk for adverse outcomes.[@ehaa121-B47] There are thus several reasons to study HR as predictor of response in clinical trials. The signal may be confounded by treatment with beta blockers.

We now have three published contemporary sham-controlled studies with the RF Spyral catheter and the US Paradise catheter, and a study-level meta-analysis of these data in addition to other sham-controlled studies has demonstrated a clear reduction in BP with RDN.[@ehaa121-B5] These studies, along with the Radiosound trial,[@ehaa121-B12] which allowed a direct, between-group comparison of these technologies, provide an opportunity for a more detailed meta-analysis of individual participant data by a third-party independent academic institution. Indeed, the use of individual participant data instead of aggregate data in meta-analyses has many potential advantages, both statistically and clinically. The aim of such a meta-analysis would be to search for predictors of the BP response to RDN in a larger population of patients using newer machine learning and unsupervised methods.

Consensus statement 3: Considerations for trial design
------------------------------------------------------

-   A practical, predictable, non-invasive, and pre-procedural measure to identify optimal RDN candidates remains an unmet need (similar markers that predict response to other device-based therapies are also desired).

-   Current recommendations to demonstrate a minimum of 10 mmHg reduction in office SBP or 6--7 mmHg in 24-h or daytime ambulatory SBP in hypertension device-based trials remain unchanged. There remains no consensus regarding what magnitude of BP reduction and at what time point defines a responder.

-   Greater consistency among RDN trials of definitions and timing of response is desirable. The most suitable time point for analysis of the BP endpoint appears to be between 2 and 6 months.

-   Heart rate as predictor of response should be further studied in clinical trials.

-   A meta-analysis of individual participant data of contemporary trials of RDN should be conducted, e.g. to identify potential predictors of BP response to RDN.

### Blood pressure and adherence measurements

The need for consistent and validated BP measurement methods in device-based hypertension trial is of major importance. Ambulatory BP, home BP, and office BP measurements provide complementary information. An ideal trial should include all three methods to optimize the precision of the analysis with validated devices according to guidelines.[@ehaa121-B48] Most wearable digital tools were developed as consumer products for fitness purposes and are not suitable for medical use. Whichever measurement is used, it is important not to allow BP measurements to influence patient behaviour in the trial setting.

Patient adherence to the medication is an important confounding factor in hypertension trials and should be assessed in any device-based hypertension therapy trial. Taking adherence into account can also save costs by reducing the need to enroll additional patients to compensate for low adherence. Only three good alternatives for adherence monitoring exist at the time of writing: drug assay, electronic monitoring, and digital monitoring. Interview questionnaires, pill count, and refill data are all unreliable and selective. Directly observed treatment is useful but logistically burdensome, and requires the patient to attend the caregiver that day.[@ehaa121-B49] Mobile health applications are appealing and may have value to patients,[@ehaa121-B50] but there is evidence from other clinical fields of 'technology fatigue' over time.[@ehaa121-B51] Drug assays have been used successfully in device-based hypertension therapy trials.[@ehaa121-B52] Absence of a medication in a urine sample is a strong sign of non-adherence. Drug levels will depend on the pharmacological profile of the drug as well as on the metabolic profile of a patient. It is important to sample frequently, to avoid measurement bias from patients' modifying their behaviour before a prespecified visit, a phenomenon known as 'white-coat adherence'.[@ehaa121-B49] Electronic monitoring is one of the most reliable techniques to diagnose poor adherence and seems to be similarly accurate as well as cheaper than drug assays.[@ehaa121-B53] The most recent method, digital monitoring relies on tiny ingestible sensors incorporated in the pill which are activated in the stomach and generating a unique message on medication and dose which is recorded together with date and time by a wearable patch worn by the patient.[@ehaa121-B54] While highly accurate, such systems remain prohibitively expensive to date.

Consensus statement 4: Tools for measuring blood pressure
---------------------------------------------------------

-   Ambulatory BP, home BP, and office BP measurements provide complementary information; at least one office and one out-of-office BP measurement technique should be utilized.

-   Adherence assessment by direct methods should be included in device-based hypertension therapy trial protocols.

### Sham or no sham in 2020?

The most recent trials in RDN were all sham-controlled.[@ehaa121-B5]^,^[@ehaa121-B6]^,^[@ehaa121-B8] A sham-control group as well as allocation concealment are necessary to avoid selection and allocation biases, performance and evaluation bias, and cointerventions (provision of unintended care to either comparison group) especially for proof of concept studies designed to establish BP lowering efficacy in small groups of highly selected patients. A sham design trial is necessary when assessing the efficacy of even established device-based techniques on parameters other than BP in hypertensive patients or extending the indication of a device-based approach to other diseases \[CKD, HF, atrial fibrillation (AF), etc.\]. However, a sham group would not be appropriate for future trials using technologies which have already proven their BP lowering efficacy in pivotal sham-controlled studies. In pharmacotherapy trials, a placebo is not ethically defensible once a treatment has been shown to be beneficial.[@ehaa121-B55] Ethical considerations are highly relevant with device-based therapies because of the associated procedural risk. Although no safety signals were observed in the studies published up to date, a sham procedure is not as risk-free as a placebo pill.

Consensus statement 5: To sham or not to sham
---------------------------------------------

-   Assuming the ongoing pivotal trials of the SPYRAL (NCT02439775; NCT02439749) and RADIANCE TRIO, REQUIRE, and RADIANCE II (NCT03614260) programmes confirm the efficacy and safety of RDN in 2020/2021, the group considers sham controls to be no longer necessary in trials using established RDN technologies examining BP lowering efficacy.

-   On the same assumptions, the Group considers sham control trials to be no longer or very rarely necessary in established device-based hypertension technologies evaluating procedural safety.

-   Sham control should remain a requirement for newer indications (CKD, HF, AF etc.) or for outcomes not previously assessed in prior trials using a given technology.

-   Sham control should remain a requirement for newer, unproven technologies.

### Withdrawal of medication in responders

Another topic of discussion was the withdrawal of antihypertensive medication in patients on multidrug regimens who are controlled after the procedure. A recent meta-analysis of patients on pharmacotherapy suggests a substantial proportion of successfully treated patients, mostly elderly, might be withdrawn from antihypertensive therapies without rebound effects and with only a small risk for minor side effects.[@ehaa121-B56] Successful drug withdrawal in patients after device-based hypertension treatment would reduce risks with the long-term use of antihypertensive drugs, with additional benefit of lower medication burden. Although most antihypertensive drugs are generic and of low cost to payers, the cost of medications and their side effects as well as the treatment burden might impact reimbursement decisions. In the majority of patients, antihypertensive medication will be re-introduced or intensified after primary endpoint collection to achieve BP control which may complexify the assessment of efficacy. There was consensus among the delegates on the desirability to include a limited drug-withdrawal period (e.g. after 1 or 2 years) in clinical trials with device-based hypertension therapies to address the issue of long-term efficacy. A drug-withdrawal assessment must be formalized (typically 4--6 weeks) and closely monitored, and it would need patient's consent. The Group felt this would be the only way to assess long-term efficacy with minimal confounding.

Consensus statement 6: Assessment of durability
-----------------------------------------------

-   Assessment of long-term efficacy is challenging. Clinical trials with device-based hypertension therapies should include a limited drug-withdrawal period at longer-term follow-up (1--2 years) to address the issue of long-term efficacy in the absence of antihypertensive medication, when considered safe.

Safety
------

For any device-based approach, injury of the treated vessel (acute or long-term), vascular access site and access-related complications, as well as organ injury (e.g. kidney and brain) and renal artery injury need to be ascertained. Given the relative novelty of device-based hypertension treatment there is no current consensus on standardized definitions of safety criteria for trials or registries, although needed. Standardized definitions of safety criteria for trials and registries in device-based hypertension therapies need to be developed. Bleeding complications after cardiac procedures are typically classified using Valve Academic Research Consortium (VARC-2) criteria[@ehaa121-B57] for TAVI or Bleeding Academic Research Consortium (BARC) criteria[@ehaa121-B58] for patients receiving antithrombotic therapy and undergoing coronary revascularization. Valve Academic Research Consortium-2 has included the BARC classification in the system. It would seem reasonable to include VARC-2-like criteria in a classification system for device-based hypertension trials and expand with standardized criteria for acute kidney and vascular injuries. The time frame for safety evaluation should also be standardized. For acute events, it may be appropriate to use a similar definition as for other procedures: an event is any encounter with the healthcare system within 30 days.[@ehaa121-B57]^,^[@ehaa121-B58] For vascular safety a time period of 6--12 months seems reasonable. Long-term safety data should be collected at 1 and 3 years.

Consensus statement 7: Definition of safety endpoints
-----------------------------------------------------

-   Standardized definitions of safety criteria for trials and registries need to be developed. Based on VARC-2 criteria and expanded with acute kidney and vascular injuries these standardized definitions would enable safety assessments to be comparable within and between device-based hypertension therapies.

-   For acute events, a similar definition as for surgical procedures would be appropriate, defining an event as any encounter with the healthcare system within 30 days.

-   For vascular safety, a time period of 6--12 months appears reasonable. The time point for long-term safety analysis is longer and should be between 1 and 3 years.

Long-term data and registries
-----------------------------

The group underlined the value of well-defined registries monitored regularly for data accuracy and completeness. These registries are particularly relevant for detection of rare events and for collecting information on novel devices use in real-world patients treated across multiple geographies. Registries are an irreplaceable source of clinical research data to support long-term safety and effectiveness claims. The global SYMPLICITY Registry has provided data on renal RF ablation for up to 3 years.[@ehaa121-B59] Such information is becoming critical: the European Union's medical device regulation came into force in 2017 with a transition time of 3 years. The new rules confer notified bodies increased post-market surveillance authority. Annual safety and performance reporting are increasingly required by device manufacturers. For registries from clinical trials to be valuable, many matters need to be decided. Data collecting needs to be comparable between trials. Therefore, a consensus on what data should be collected, sample size, follow-up duration, timing of data collection, and selection of outcomes has to be provided. To design and implement such standards, a dedicated effort from the community of clinical trialists is needed. Registries have well-known disadvantages compared with controlled trials: the information collected is typically less detailed, there is greater loss of follow-up and adherence to protocols is usually handled less strictly. A way to increase data collection is to link reimbursement to registry participation, as has been trialled in some contexts, e.g. the German Aortic Valve Registry (GARY).[@ehaa121-B60]

Consensus statement 8: Real-world registries
--------------------------------------------

-   Registries should be set up whenever possible with standardized protocols for what data to collect, follow-up duration, timing of data collection, outcomes, and more.

-   To drive this standardization a dedicated effort from the community of clinical trialists will be needed.

-   Ideally, and when feasible, these registries should be connected to national administrative health databases to automatically retrieve information about vital status, causes of hospitalization and causes of death.

-   Cross country comparisons are valuable, they require special attention to the requirements of the General Data Protection Regulation.

Patient-related outcomes
------------------------

As noted above, regulatory bodies are paying increasing attention to patients' experience of illness and treatment when considering marketing approvals and claims. Early interaction with regulatory agencies is highly recommended when planning to include PROs in support for labelling claims or for use in reimbursement discussions. Healthcare professionals owe it to patients to inform appropriately on matters such as what to expect of a treatment; differences between average results and individual results, and how to judge risk. Patients' expectations and attitudes will influence PROM. Terms need to be presented in ways the general public understands, including much that is self-evident to physicians. There may also be discrepancies between effects that the physician may consider a positive outcome and what patients may experience---positively or negatively---as PROs. The community needs to build the tools necessary to capture PROs and ensure they are validated and standardized. This should be done starting from existing tools for consistency. A number of publications have concerned themselves with the process for constructing quality PRO instruments, from conceptual model development through instrument validation.[@ehaa121-B61] As highlighted in guidance from the US Food and Drug Administration (FDA)[@ehaa121-B62] substantial patient input should be included in PRO development. Of note, the hierarchy between PRO and traditional endpoints is not clear.

Patient preferences are different from PROM, although both may be considered as part of patient experience. Patient-reported outcome instruments measure a patient's perception of health status before, during, and after therapy. In contrast, patient-preference studies examine how patients rank treatment decisions and how treatment attributes may influence treatment choices. The FDA guidance on this topic[@ehaa121-B63] states that reviewers may consider 'patient tolerance for risk and perspective on benefit' as an additional factor during reviews of approval applications when this information is available and qualifies as scientific evidence. Patient-preference data can measure the likely size of the population for whom the benefits of a treatment outweigh the risks.

Consensus statement 9: Patient-related outcome metrics
------------------------------------------------------

-   PROs reflect a key dimension of overall disease burden and should be a primary aim of disease management to improve patient well-being. An opportunity for future study relates to the development of PRO models specific to device-based therapies for hypertension.

-   PRO and patient-preference should be part of future clinical studies.

-   Physicians should be trained on eliciting and respecting patients' preference in shared decision processes and on the application and interpretation of PROs.

Considerations for regulatory and reimbursement authorities
-----------------------------------------------------------

Any discussion of the future role of device-based hypertension treatment needs to take into account the changing health care landscape, where value-based systems are becoming ever more important. Value in health care has been defined as outcomes relative to cost.[@ehaa121-B64] The possible relationships between cost and effectiveness are outlined in *Figure [3](#ehaa121-F3){ref-type="fig"}*. The ideal scenario of lower cost for greater effectiveness compared with existing treatments is unlikely to be observed in hypertension treatment. Reimbursement authorities will have to set an effectiveness-cost threshold, which is decided at national levels in Europe.

![Cost-effectiveness plane. Adapted from Bulsei *et al*.[@ehaa121-B65]](ehaa121f3){#ehaa121-F3}

After the SYMPLICITY HTN trials, a number of health-economic studies were conducted modelling the cost-effectiveness of RDN in various countries and healthcare systems.[@ehaa121-B66] With the advent of new, proven technologies, an explosion of such activity can be expected. A number of challenges to such analyses have recently been summarized.[@ehaa121-B65] For trialists, the challenge is to demonstrate value by maximizing outcomes. This means selecting those patients most likely to respond and in whom the treatment affects high-impact outcomes, typically high-risk groups. A value-focused selection criterion may be the potential for the greatest efficiency of procedure, to reduce the cost factor in economic modelling. Reimbursement bodies may appreciate endpoints which predict the development of HF, AF or end-stage renal disease, but the time horizon needs to be considered. Some long-term endpoints may be more suitable for inclusion in a registry, although evidence of key benefits beyond BP reduction may need demonstration in a controlled trial, at least initially.

Two important assumptions are usually made when modelling hypertension data: that treatment remains effective long-term and that treatment-induced reductions in BP reduces the risk of events in an expected manner per unit reduction of BP. For device-based hypertension therapies both assumptions need to be proven. The effectiveness of a drug investigated in a trial tends to be higher than in real life, however,[@ehaa121-B71]^,^[@ehaa121-B72] which indicates the necessity for registry data to complement the evidence-base.

Consensus statement 10: Cost-effectiveness evaluation
-----------------------------------------------------

-   Additional clinical evidence is needed for the assumptions that device-based hypertension treatment remains effective long-term and that device treatment-induced reductions in BP reduces the risk of events similar to drug treatment reductions in BP as well as to estimate the cost effectiveness in the various candidate populations.

-   The time point for economic evaluations and to identify changes in resource utilization should be between 1 and 3 years.

Potential future indications for neuromodulation therapies
----------------------------------------------------------

Most clinical trials in device-based hypertension therapies to date have focused on demonstrating BP reductions in patients with uncontrolled hypertension. After the recent crop of consistently successful trials, the question arises whether the time has come to explore device-based autonomic modulation in other CV diseases such as HF, arrhythmias or in hypertensive patients with CKD. Such trials would signal a shift in focus from reducing BP towards neuromodulation, which is a factor in the aetiology of both HF and AF but also metabolic syndrome.[@ehaa121-B73]

Renal denervation has been studied in smaller trials in HF but the evidence to date remains inconclusive.[@ehaa121-B74] Hypertension is the most relevant risk factor for onset and recurrence of AF.[@ehaa121-B77]^,^[@ehaa121-B78] In patients with AF and HTN, RDN was investigated as adjunct to pulmonary vein isolation (PVI) with favourable results on AF recurrence and BP.[@ehaa121-B77] It remains elusive whether the neurohormonal effect of RDN or its BP lowering effect is the main factor driving these results. New evidence may be provided by the multicentre SYMPLICITY-AF (NCT02064764) and ASAF (NCT02115100) trials, which evaluate the safety and effectiveness of performing both RDN and PVI simultaneously in patients with paroxysmal and persistent AF and uncontrolled hypertension (SBP \>140 mm Hg, despite ≥1 antihypertensive drug).

Consensus statement 11: Extended potential indications for neuromodulation therapies, beyond hypertension
---------------------------------------------------------------------------------------------------------

-   The confirmation of the biological proof-of-principle of RDN has provided the rationale for further study of device-based neuromodulation in other indications such as HF, arrhythmias, CKD, and metabolic syndrome.

-   The next step should be carefully designed, sham-controlled, feasibility studies in these new indications with blinded evaluation of both efficacy and safety endpoints.

Outlook
-------

After several years in the doldrums, device-based therapy for hypertension has returned as one of the promising and novel treatment approaches on the horizon. However, it should be remembered that other effects beyond BP lowering remain to be demonstrated: improvement in outcomes, health-economic value, and benefits on PROs, to name just a few. For RDN to be ready for a wider uptake among patients, physicians and health authorities, reliable predictors of response should be identified. Identifying a reliable and uncomplicated intra-procedural validation method to assess the completeness of the ablation remains a fundamental challenge. Approaches to identify candidate most likely to respond to RDN include BP response to high-frequency renal nerve stimulation, reflex elicitation using a physiological stimulus and other methods,[@ehaa121-B79] but no simple front-runner technique has emerged to date. Other devices need to provide biological proof of principle and safety, before pivotal studies can be initiated. If data continue to support device-based hypertension therapies and the critical needs can be fulfilled, the technologies may be applied to a number of vulnerable groups of patients with hypertension. With the help of local health care systems, of international bodies and device companies, a development plan of device-based treatment at low cost should be implemented in low-income countries to treat the most vulnerable patients with hypertension at very high risk of hypertension-related complications.
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